cabozantinib
exelixis
['cabometyx', 'bladder']
despite its favorable safety profile, cabometyx was not superior to placebo when it was added after chemo to treat bladder cancer. future trials should consider combining novel agents with maintenance immunotherapy, a researcher said at #asco22 
Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.